Literature DB >> 26722275

Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.

Kyoko Inadomi1, Hozumi Kumagai1, Kotoe Takayoshi1, Hiroshi Ariyama1, Hitoshi Kusaba1, Akihiro Nishie2, Hidetaka Yamamoto3, Ken Takase4, Mamoru Tanaka1, Kosuke Sagara1, Yuta Okumura1, Kenta Nio1, Michitaka Nakano1, Shuji Arita1, Yoshinao Oda3, Koichi Akashi1, Eishi Baba5.   

Abstract

A 64-year-old male presented with increased abdo-minal fullness and fever. Radiological examination revealed moderate ascites, a tumor with a diameter of 12.5 cm in the mesenteric region, as well as multiple tumors in the thoracic and abdominal para-aortic regions and in the left supraclavicular regions. Pathohistological findings of the biopsy specimen revealed atypical spindle cells accompanied by infiltration of lymphocytes. The plasmacytes were positive for CD68, murine double minute 2 and S-100, while they were negative for α-smooth muscle actin, cyclin-dependent kinase 4 and anaplastic lymphoma kinase. Clinically, the patient presented systemic symptoms and laboratory results indicated an elevation in the inflammatory response, while the CT and MRI findings were consistent with an inflammatory myofibroblastic tumor (IMT). Based on the clinical and histological findings, the patient was diagnosed with IMT. In total, 4 cycles of combination chemotherapy with doxorubicin and ifosfamide were administered. Tumor size reduction by 50% was achieved subsequent to the 4th chemotherapy cycle. In conclusion, successful control of this rare metastatic IMT was achieved by systemic chemotherapy.

Entities:  

Keywords:  anaplastic lymphoma kinase rearrangement negative; chemotherapy; inflammatory pseudotumor; metastatic inflammatory myofibroblastic tumor

Year:  2015        PMID: 26722275      PMCID: PMC4665821          DOI: 10.3892/ol.2015.3708

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs.

Authors:  R Przkora; U Bolder; S Schwarz; K W Jauch; J Spes; R Andreesen; A Mackensen
Journal:  Eur J Clin Invest       Date:  2004-04       Impact factor: 4.686

3.  The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study.

Authors:  Harry Applebaum; Mark W Kieran; Timothy P Cripe; Cheryl M Coffin; Margaret H Collins; Arja Kaipainen; Andrea Laforme; Robert C Shamberger
Journal:  J Pediatr Surg       Date:  2005-06       Impact factor: 2.545

4.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: 
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

5.  MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre-Garau; Louis Guillou; Gonzague de Pinieux; Philippe Terrier; Réal Lagacé; Alain Aurias; Isabelle Hostein; Jean Michel Coindre
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

6.  p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.

Authors:  H Yamamoto; Y Oda; T Saito; A Sakamoto; K Miyajima; S Tamiya; M Tsuneyoshi
Journal:  Histopathology       Date:  2003-05       Impact factor: 5.087

Review 7.  Successful treatment of an unresectable inflammatory myofibroblastic tumor of the frontal bone using a cyclooxygenase-2 inhibitor and methotrexate.

Authors:  Fumiko Kusunoki-Nakamoto; Takashi Matsukawa; Masaki Tanaka; Toji Miyagawa; Tomotaka Yamamoto; Jun Shimizu; Masako Ikemura; Junji Shibahara; Shoji Tsuji
Journal:  Intern Med       Date:  2013-03-01       Impact factor: 1.271

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine.

Authors:  Francesca Favini; Antonio Giordano Resti; Paola Collini; Michela Casanova; Cristina Meazza; Giovanna Trecate; Andrea Ferrari
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

Review 10.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

View more
  2 in total

1.  Endobronchial Inflammatory Myofibroblastic Tumour-A Case Report.

Authors:  Vishnukanth Govindaraj; Debasis Gochhait; Balla Nagamalli Kumar; Suryakala Narayanasami
Journal:  J Clin Diagn Res       Date:  2016-08-01

2.  Relapsed and unresectable inflammatory myofibroblastic tumor responded to chemotherapy: A case report and review of the literature.

Authors:  Yasuhiro Maruyama; Toshirou Fukushima; Daisuke Gomi; Takashi Kobayashi; Nodoka Sekiguchi; Akiyuki Sakamoto; Shigeru Sasaki; Keiko Mamiya; Tomonobu Koizumi
Journal:  Mol Clin Oncol       Date:  2017-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.